Document is current
Any future updates will be listed below
-
Authors
Turki, Amin T. https://orcid.org/0000-0003-1347-3360
Fan, Yi
Hernández-Sánchez, Alberto https://orcid.org/0000-0002-6601-3096
Silva, Wellington
Fleming, Shaun
Yalcin, Koray
Van Elssen, Catharina H.M.J.
Madanat, Yazan https://orcid.org/0000-0001-9573-2690
Karasek, Magdalena https://orcid.org/0000-0002-1425-5421
Aljurf, Mahmoud
Della Porta, Matteo G. https://orcid.org/0000-0002-6915-5970
Martinez-Roca, Alexandra https://orcid.org/0000-0003-2143-5356
Guarnera, Luca
Steffen, Katarina
Antoniou, Evangelia
Rivas, Maria M. https://orcid.org/0000-0001-7136-765X
Mishra, Deepak K.
Blum, Ansgar T.
Manantsoa, Stephania Niry
Adiat, Adeniyi
Enshaei, Amir https://orcid.org/0000-0002-7464-0743
Thol, Felicitas https://orcid.org/0000-0001-5848-6152
Voso, Maria Teresa https://orcid.org/0000-0002-6164-4761
Chen, Jia
Elhassan, Tusneem Ahmed
Moorman, Anthony V. https://orcid.org/0000-0002-9781-6107
Vidriales, María Belén
Neuendorff, Nina R.
Koc, Ahmet
Mishra, Pratyush
Strumberg, Dirk
Fourmanov, Roma S.
Heine, Lukas
Kleesiek, Jens https://orcid.org/0000-0001-8686-0682
Munárriz, Daniel
Asti, Gianluca
Mokoonlall, Mridula https://orcid.org/0009-0002-1995-2397
Kometas, Marisa
Rego, Eduardo
Mecklenbrauck, Rabea https://orcid.org/0009-0005-9374-300X
Sobas, Marta
Wu, Depei https://orcid.org/0000-0002-6312-3863
Nensa, Felix https://orcid.org/0000-0002-5811-7100
Engelke, Merlin https://orcid.org/0000-0002-8463-8786
- License Information
-
More Information
Article History
Received: 10 June 2025
Accepted: 2 March 2026
First Online: 20 March 2026
Competing interests
: A.T.T.: Consultancy for Maat Pharma, Onkowissen.tv, CSL Behring, Biomarin, Oncopeptides and Pfizer, research funding by Neovii, travel reimbursement by Novartis and Neovii; YFM has received honoraria/consulting fees from BMS, Kura Oncology, BluePrint Medicines, Geron, OncLive and MD Education, VJHemOnc, Curio Science, and Medscape Live. YFM participated in advisory boards and received honoraria from Stemline Therapeutics, Blueprint Medicines, Taiho Oncology, SOBI, Rigel Pharmaceuticals, Geron, Cogent Biosciences and Abbvie. YFM received travel reimbursement from MD Education; A.M.R.: Consultant or advisory role (Bristol Myers Squibb, Abbvie, Kite Gilead), travel grants (Kite Gilead, Roche, Takeda, Janssen, Abbvie, Jazz Pharmaceuticals), speaker (Abbvie, Gilead). M.T.V: Consultant or advisory role (Bristol Myers Squibb, Novartis, Sobi, AOP), travel grants (Novartis), speaker (Bristol Myers Squibb, Novartis, Sobi, AOP); M.S.: Consultant or advisory role (Bristol Myers Squibb, Astellas Servier), travel grants (Servier), speaker (Bristol Myers Squibb, Astellas, Servier, Abbvie, Daychi-Sankyo). The remaining authors declare no competing interests.
